UW coronavirus vaccine shows strong immune response in monkeys, mice
- July 20, 2020
The University of Washington and Seattle-based HDT Bio Corp. announced the development of a promising COVID-19 vaccine candidate that uses a cutting-edge approach. Based on preliminary studies, HDT Bio has taken steps toward garnering FDA approval for phase one human trials, planned for late 2020.